Organization (Hospital)
The Affiliated Hospital of Hangzhou Normal University
ClinicalTrials.gov lists The Affiliated Hospital of Hangzhou Normal University as lead sponsor of 10 trials. It has 7 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers The Affiliated Hospital of Hangzhou Normal University: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (40)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Fatty Liver | 4 |
| Coronary Artery Disease | 3 |
| Coronary Disease | 3 |
| Migraine Disorders | 3 |
| Non-alcoholic Fatty Liver Disease | 3 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 6 |
| 2019 | 1 |
| 2017 | 3 |
| 2016 | 2 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Transcranial Magnetic Stimulation Sham | Fatty Liver | Not reported | 1 |
| Transcranial Magnetic Stimulation Sham | Insulin Resistance | Not reported | 1 |
| Transcranial Magnetic Stimulation Sham | Liver Diseases, Alcoholic | Not reported | 1 |
| Transcranial Magnetic Stimulation Sham | Substance-Related Disorders | Not reported | 1 |
| Transcranial Magnetic Stimulation Sham | Metabolic Syndrome | Not reported | 1 |
Showing 5 of 7 active programs.
Journals published in (47)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 10 |
| Journal of the American College of Cardiology | 7 |
| Hepatology (Baltimore, Md.) | 5 |
| JACC. Cardiovascular interventions | 4 |
| Lancet (London, England) | 4 |
Showing 5 of 47 journals.
Organization relationships (48)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Co sponsors trial with | 4 |
| First Affiliated Hospital Zhejiang University | Co sponsors trial with | 3 |
| Hangzhou Hospital of Traditional Chinese Medicine | Co sponsors trial with | 2 |
| Guiyang Medical University | Co sponsors trial with | 2 |
| Second Affiliated Hospital of Soochow University | Co sponsors trial with | 2 |
Showing 5 of 48 relationships.
Latest dated events (35)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 35 events.
Biomarker capability evidence (60)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CBR1 | Trial collaborator | Named in trial inclusion criteria |
| CORIN | Trial collaborator | Named in trial inclusion criteria |
| CRNKL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 60 evidence rows.
Biomarkers this organization publishes on (37)
Shown in this order: most publications first.
Showing 5 of 37 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.